^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    RAD51 overexpression

    i
    Other names: RAD51, RAD51 Recombinase, BRCA1/BRCA2-Containing Complex Subunit 5, DNA Repair Protein RAD51 Homolog 1, RAD51 Homolog A, HRAD51, RAD51A, RECA, RAD51 Homolog (RecA Homolog, E. Coli) (S. Cerevisiae), RAD51 (S. Cerevisiae) Homolog (E Coli RecA Homolog), RAD51 Homolog (S. Cerevisiae), RecA E. Coli Homolog Of, Recombination Protein A RecA-Like Protein, HsT16930, HsRad51, HsRAD51, BRCC5, FANCR, MRMV2
    Entrez ID:
    5888
    Related biomarkers:
    Expression
    Mutation
    Fusion
    over1year
    Bleomycin induces senescence and repression of DNA repair via downregulation of Rad51. (PubMed, Mol Med)
    Our works suggest that the inhibition of Rad51 plays a pivotal role in bleomycin-induced AECs senescence and lung injury, offering potential strategies to alleviate the pulmonary toxicity of bleomycin.
    Journal
    |
    RAD51 (RAD51 Homolog A) • E2F1 (E2F transcription factor 1)
    |
    RAD51 overexpression
    |
    bleomycin
    over1year
    Long non-coding RNA RAD51-AS1 promotes the tumorigenesis of ovarian cancer by elevating EIF5A2 expression. (PubMed, J Cancer Res Clin Oncol)
    RAD51-AS1 promoted OvCA progression by the regulation of the miR-140-3p/EIF5A2 axis, which illustrated the potential therapeutic target for OvCA.
    Journal
    |
    RAD51 (RAD51 Homolog A) • EIF5A2 (Eukaryotic Translation Initiation Factor 5A2) • MIR140 (MicroRNA 140)
    |
    RAD51 overexpression
    almost2years
    Targeting NEAT1 Affects the Sensitivity to PARPi in Serous Ovarian Cancer by Regulating the Homologous Recombination Repair Pathway. (PubMed, J Cancer)
    NEAT1 expression could predict response to chemotherapy for ovarian cancer. NEAT1 knockdown inhibited HR capacity and increased DNA damage caused by Olaparib in serous ovarian cancer cells, making them more sensitive to Olaparib and providing a crucial therapeutic advantage of increasing sensitivity to Olaparib.
    Journal • BRCA Biomarker • PARP Biomarker
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • HRD (Homologous Recombination Deficiency) • RAD51 (RAD51 Homolog A) • NEAT1 (Nuclear Paraspeckle Assembly Transcript 1) • FOXM1 (Forkhead Box M1) • H2AX (H2A.X Variant Histone)
    |
    BRCA2 mutation • BRCA1 mutation • RAD51 overexpression
    |
    Lynparza (olaparib)
    almost2years
    Rad51 and Systemic Inflammatory Indicators as Novel Prognostic Markers in Esophageal Squamous Cell Carcinoma. (PubMed, Technol Cancer Res Treat)
    Our study found a close correlation between elevated Rad51 expression and inflammatory markers. High Rad51 expression, high neutrophil-to-lymphocyte ratio, and low lymphocyte-to-monocyte ratio are associated with lower survival rates. The combined assessment of Rad51 and inflammatory markers can be useful for preoperative assessment and prognostic evaluation in esophageal squamous cell carcinoma patients.
    Journal
    |
    RAD51 (RAD51 Homolog A) • CRP (C-reactive protein)
    |
    High NLR • RAD51 overexpression • Albumin-L
    almost2years
    The protein phosphatase EYA4 promotes homologous recombination (HR) through dephosphorylation of tyrosine 315 on RAD51. (PubMed, Nucleic Acids Res)
    Depletion of EYA4 decreases single-stranded DNA accumulation following DNA damage and impairs HR, while overexpression of EYA4 in cells promotes dephosphorylation and stabilization of RAD51, and thereby nucleoprotein filament formation. Our data have implications for a pathological version of RAD51 in EYA4-overexpressing cancers.
    Journal
    |
    RAD51 (RAD51 Homolog A)
    |
    ALK rearrangement • RAD51 overexpression
    almost2years
    Differential impact of cytoplasmic vs. nuclear RAD51 expression on breast cancer progression and patient prognosis. (PubMed, Int J Oncol)
    The current data suggest that differential expression of subcellular RAD51 had a distinct impact on breast cancer progression and patient survival. Specifically, cytoplasmic RAD51 in contrast to nuclear RAD51 was potentially an adverse marker in breast cancer.
    Journal
    |
    RAD51 (RAD51 Homolog A)
    |
    RAD51 overexpression
    2years
    Enhanced Genomic Stability in Monomorphic Post-Transplant Lymphoproliferative Disorders Is Driven By Distinct Mechanisms Stratified By EBV Status (ASH 2023)
    Like HIV associated DLBCL, these results show that PTLD is more genomically stable than IC-DLBCL, and that genomic stability is further enhanced in EBV(+)PTLD which have increased expression of UPS related genes. In contrast, EBV(-)PTLD have increased expression of DNA damage repair genes, including RAD51. In summary, monomorphic DLBCL PTLD tumors have enhanced genomic stability that appears to be mediated by two distinct mechanisms stratified by EBV status.
    Post-transplantation
    |
    MSH6 (MutS homolog 6) • MSH2 (MutS Homolog 2) • FBXW7 (F-Box And WD Repeat Domain Containing 7) • CHEK2 (Checkpoint kinase 2) • RAD51 (RAD51 Homolog A) • FANCA (FA Complementation Group A) • EP300 (E1A binding protein p300) • CHEK1 (Checkpoint kinase 1) • NBN (Nibrin Nijmegen Breakage Syndrome 1 (Nibrin)) • CCNA2 (Cyclin A2) • PCNA (Proliferating cell nuclear antigen) • DDB2 (Damage Specific DNA Binding Protein 2) • ERCC3 (ERCC Excision Repair 3, TFIIH Core Complex Helicase Subunit) • FANCE (FA Complementation Group E) • POLG2 (DNA Polymerase Gamma 2, Accessory Subunit) • FANCB (FA Complementation Group B)
    |
    RAD51 overexpression • ATM expression
    |
    nCounter® PanCancer Pathways Panel
    2years
    RAD51 is a poor prognostic marker and a potential therapeutic target for oral squamous cell carcinoma. (PubMed, Cancer Cell Int)
    RAD51 is a poor prognostic marker for oral squamous cell carcinoma. High RAD51 protein expression associates with resistance to chemotherapy and radiotherapy. Addition of B02 significantly increased the cytotoxicity of cisplatin. These findings suggest that RAD51 protein may function as a treatment target for oral cancer.
    Journal
    |
    RAD51 (RAD51 Homolog A)
    |
    RAD51 overexpression
    |
    cisplatin
    over2years
    miR-4796 enhances the sensitivity of breast cancer cells to ionising radiation by impairing the DNA repair pathway. (PubMed, Breast Cancer)
    The findings here suggest that miR-4796 can enhance radiation-induced cell death by directly targeting multiple DDR components, and repress NHEJ and HR DNA repair pathways. miR-4796 can act as an effective radiation sensitising agent.
    Review • Journal • BRCA Biomarker • PARP Biomarker
    |
    BRCA1 (Breast cancer 1, early onset) • RAD51 (RAD51 Homolog A) • PARP1 (Poly(ADP-Ribose) Polymerase 1)
    |
    ATM overexpression • RAD51 overexpression • ATM expression • miR-128 expression • miR-1287 expression
    over2years
    A tumor immune microenvironment-based model for prediction of everolimus efficacy in premenopausal women with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: Preliminary results from MIRACLE trial (ESMO 2023)
    The results also showed that patients whose tumors were non-responsive to EVE (P = 0.00021) or whose PFS was poor (P = 0.0025) were at a higher risk in the model. Conclusions The immune-related gene model consisting of HDC, TNFRSF1A, and RAD51 could potentially predict the efficacy of EVE in premenopausal patients with HR+/HER2− ABC with endocrine resistance, which could help stratify responders to EVE and guide the choice of EVE in clinical practice.
    Clinical • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • CD8 (cluster of differentiation 8) • RAD51 (RAD51 Homolog A) • TNFRSF1A (TNF Receptor Superfamily Member 1A)
    |
    HR positive • HER-2 negative • EGFR positive • RAD51 overexpression
    |
    everolimus
    almost3years
    HPV and RAD51 as Prognostic Factors for Survival in Inoperable Oral and Oropharyngeal Cancer in Patients Unfit for Chemotherapy Treated with Hyperfractionated Radiotherapy. (PubMed, Medicina (Kaunas))
    We found no statistically significant differences but detected trends toward improvement in the survival of HPV-positive and RAD51 overexpressing patients unfit for surgical treatment or chemotherapy treated with hyperfractionated radiotherapy. The trends, however, indicate that in a larger group of patients, the effects of these two parameters would likely be statistically significant.
    Journal
    |
    RAD51 (RAD51 Homolog A)
    |
    RAD51 overexpression